Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Beginning Cash Balance: 2009-2024

Historic Beginning Cash Balance for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $92.2 million.

  • Ironwood Pharmaceuticals' Beginning Cash Balance fell 12.01% to $92.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.2 million, marking a year-over-year decrease of 20.86%. This contributed to the annual value of $92.2 million for FY2024, which is 85.99% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Beginning Cash Balance stood at $92.2 million for FY2024, which was down 85.99% from $657.9 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Beginning Cash Balance ranged from a high of $657.9 million in FY2023 and a low of $92.2 million during FY2024.
  • For the 3-year period, Ironwood Pharmaceuticals' Beginning Cash Balance averaged around $456.7 million, with its median value being $620.1 million (2022).
  • In the last 5 years, Ironwood Pharmaceuticals' Beginning Cash Balance surged by 105.08% in 2021 and then slumped by 85.99% in 2024.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Beginning Cash Balance stood at $177.0 million in 2020, then surged by 105.08% to $363.0 million in 2021, then spiked by 70.81% to $620.1 million in 2022, then grew by 6.10% to $657.9 million in 2023, then plummeted by 85.99% to $92.2 million in 2024.